Latest News and Press Releases

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer